

CooperVision Research at NCC Elevates Clinical Care

Scientists Share New Findings in Presbyopia, Astigmatism, Myopia Management, and More

SAN RAMON, CALIF., June 23, 2022—More than 1,000 eye care professionals (ECPs) and researchers from the Netherlands and around the world are expected to attend the [2022 Dutch Contact Lens Congress \(NCC\)](#) from June 26-27 in Eindhoven. Among them will be scientists presenting a spectrum of new findings supported by [CooperVision](#) at the NCC and the British Contact Lens Association (BCLA) collaborative research symposium, further advancing understanding of high-value clinical and practice success topics.

“By investing in and disseminating research into some of the timeliest topics in contact lenses and eye care, CooperVision is extending our commitment to help improve clinical outcomes, increase patient satisfaction, and grow the category. The papers and posters being presented at NCC 2022 offer new evidence-based insights that elevate ocular science and provide practical guidance for ECPs,” said [Francis Erard](#), Vice President of Research & Development for CooperVision.

CONTEMPORARY PRESBYOPIA MANAGEMENT

About one in three contact lens wearers today are presbyopic, which is an approximately 75% increase from two decades ago. And although multifocal contact lens fits are on the rise, they still represent about only half of lenses worn by presbyopes—representing significant growth opportunities.^[1] To support multifocal contact lens wear as presbyopia management interest becomes more prominent, CooperVision is sharing three works on the subject.

Led by a team from Ocular Technology Group, two papers focus on predicting the success of multifocal wear to build confidence among fitters. Prediction of Intention to Purchase of Multifocal Contact Lenses at Time of Dispensing (Guillon M, et al.) and Comparison of Overall Vision Satisfaction of a Multifocal Contact Lens on Dispensing and After 1-week Daily Wear to Predict Success (Guillon M, et al.) indicate that good vision at the time of dispensing is an indicator of future success.

A separate CooperVision poster is intended to extend similar confidence to ECPs prescribing recently launched MyDay® multifocal contact lenses. Wearer Experience and Eye Care Professional Acceptance with a New 1 Day Multifocal Contact Lens (McParland M, et al.) demonstrates that ‘real world’ success and wearer satisfaction for vision, comfort and overall performance were comparable to previously reported clinical trials, plus fast and easy fitting for ECPs.

BETTER OUTCOMES FOR ASTIGMATIC PATIENTS

As a global leader in toric contact lenses, CooperVision is constantly adding to a body of knowledge that helps ECPs garner better outcomes for astigmatic patients. This includes being as particular as possible in addressing astigmatism in making lens choices.

A CORE-led paper— Performance Evaluation of Two Toric Multifocal Contact Lenses Available in Different Parameter Increments (Luensmann D, et al)—suggests that fitting a toric lens that offers more axis steps (5- vs. 10-degree increments) and more near adds (6 vs. 2 options) may contribute to better patient-reported vision outcomes. Aligning with that theme, a Eurolens-authored paper—Clinical Performance of Spherical vs. Toric Soft Contact Lenses in Low and Moderate Astigmats (Mirza A, et al.)—reflected clinically meaningful superiority in visual acuity with a toric lens and very similar comfort comparing the toric lens to the sphere. This suggests ECPs should prescribe low astigmats with toric lenses for full visual correction understanding that the comfort is the same.

MYOPIA MANAGEMENT, CATEGORY GROWTH & MORE

The company will deliver a paper on its groundbreaking seven-year MiSight® 1 day* contact lens clinical trial. Twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained among the entire cohort. [\[2\]](#)†

A poster on young adult perceptions of contact lens wear, derived from new European data, offers insights into mechanisms that ECPs can employ to potentially increase new fits as well as promote dual wear of contact lenses and spectacles. A paper on using the OptiExpert™ online fitting app to support contact lens selection offers encouragement for technology-aided practice success.

Also traveling to Eindhoven are CooperVision FORCE (Future Ocular Research Creativity Event) student honorees from the University of Salento and Aston University, sharing research on the effectiveness of Biofinity Energys for accommodative support and the optimization of blink exercises using a dedicated digital app, respectively.

For additional information on NCC 2022, including sessions and speakers, visit contactlenscongress.com.

###

Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval of MiSight® 1 day.

† Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

* U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

About CooperVision

CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Media Contact

Mike McDougall, APR, Fellow PRSA, McDougall Communications

mike@mcdougallpr.com or +1-585-434-2150

[1] Contact lens prescribing for presbyopia: an update for 2020 (analysis for CooperVision Inc.). Morgan P., The University of Manchester.

[2] Myopia control treatment benefits are retained after discontinuation of a dual focus, myopia control contact lens (Lumb E, et al). Paper Presentation. NCC 2022.